Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Lung Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 22pembrolizumab 21Carboplatin 12Radiotherapy 11Paclitaxel 11Brachytherapy 11Drug Therapy 10Bevacizumab 9Blood Specimen Collection 7Colposcopy 6Specimen Handling 5Injections 5toripalimab 4Taxes 4Surveys and Questionnaires 4Nivolumab 4Mass Screening 4Human Papillomavirus DNA Tests 4Gemcitabine 4Chemotherapy, Adjuvant 4Chemoradiotherapy 4spartalizumab 3lenvatinib 3camrelizumab 3aldesleukin 3Restraint, Physical 3Radiation 3Fulvestrant 3Cyclophosphamide 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Cervical Neoplasms × cyclopropapyrroloindole × Clear all
NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 2/3 Recruiting
200 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡